Novo implemented a flexible dosing protocol, where only 57.3% of patients reached the highest dose after 68 weeks, compared to 82.5% for cagrilintide alone and 70.2% for semaglutide alone
This process is known as pharmaceutical compounding
These glucagon-like peptide-1 inhibitors (GLP-1) are also increasingly prescribed for weight loss as they are effective in: Reducing appetite and promoting a feeling of fullness, which can lead to an overall decreased caloric intake Slowing down how quickly food exits the stomach, leading to a longer period of satiety Regulating blood sugar levels and improving insulin sensitivity These medications cannot be denied their efficacy in weight loss
We anticipate an increase in burden because, in addition to the current requirement for submission of ASP data each quarter to CMS, all manufacturers are required to submit reasonable assumptions and warrantee/certification letters to accompany their ASP data submissions
Metabolic Effects When ingested, alcohol is quickly distributed throughout the body, affecting most major organs